Intra-Cellular Therapies (NASDAQ:ITCI) Stock Rating Lowered by Mizuho

Intra-Cellular Therapies (NASDAQ:ITCI - Get Free Report) was downgraded by analysts at Mizuho from an "outperform" rating to a "neutral" rating in a research note issued on Monday, Marketbeat Ratings reports. They presently have a $132.00 price objective on the biopharmaceutical company's stock, down from their prior price objective of $140.00. Mizuho's price target suggests a potential upside of 2.92% from the stock's previous close.

A number of other equities analysts have also recently weighed in on ITCI. Piper Sandler reaffirmed a "neutral" rating and set a $132.00 price objective (up previously from $107.00) on shares of Intra-Cellular Therapies in a research report on Tuesday, January 14th. StockNews.com began coverage on Intra-Cellular Therapies in a research report on Monday. They set a "hold" rating on the stock. Needham & Company LLC restated a "hold" rating on shares of Intra-Cellular Therapies in a research note on Friday, February 21st. Canaccord Genuity Group cut Intra-Cellular Therapies from a "buy" rating to a "hold" rating and boosted their price objective for the company from $119.00 to $132.00 in a research note on Friday, January 31st. Finally, JPMorgan Chase & Co. lifted their target price on shares of Intra-Cellular Therapies from $81.00 to $89.00 and gave the company an "overweight" rating in a report on Monday, November 4th. Ten equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and an average target price of $106.08.

Intra-Cellular Therapies Stock Performance

ITCI stock traded down $0.21 during midday trading on Monday, reaching $128.25. The stock had a trading volume of 1,278,873 shares, compared to its average volume of 3,911,228. The firm has a fifty day simple moving average of $112.80 and a two-hundred day simple moving average of $90.87. The stock has a market cap of $13.64 billion, a PE ratio of -147.41 and a beta of 0.72. Intra-Cellular Therapies has a 52-week low of $63.30 and a 52-week high of $129.00.

Intra-Cellular Therapies (NASDAQ:ITCI - Get Free Report) last announced its earnings results on Friday, February 21st. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.08). The company had revenue of $199.22 million during the quarter, compared to analyst estimates of $205.08 million. Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. On average, sell-side analysts predict that Intra-Cellular Therapies will post -0.64 EPS for the current fiscal year.

Insider Activity at Intra-Cellular Therapies

In related news, CEO Sharon Mates sold 51,000 shares of the business's stock in a transaction dated Wednesday, December 4th. The stock was sold at an average price of $85.80, for a total value of $4,375,800.00. Following the transaction, the chief executive officer now owns 1,070,329 shares in the company, valued at approximately $91,834,228.20. The trade was a 4.55 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 2.60% of the stock is owned by insiders.

Institutional Investors Weigh In On Intra-Cellular Therapies

Several institutional investors and hedge funds have recently made changes to their positions in the company. Accredited Wealth Management LLC acquired a new stake in shares of Intra-Cellular Therapies in the fourth quarter valued at approximately $28,000. True Wealth Design LLC purchased a new position in Intra-Cellular Therapies in the 3rd quarter worth about $32,000. GAMMA Investing LLC increased its holdings in shares of Intra-Cellular Therapies by 46.3% in the 4th quarter. GAMMA Investing LLC now owns 758 shares of the biopharmaceutical company's stock valued at $63,000 after purchasing an additional 240 shares during the period. Capital Performance Advisors LLP acquired a new stake in shares of Intra-Cellular Therapies during the 3rd quarter valued at $74,000. Finally, Venturi Wealth Management LLC bought a new position in Intra-Cellular Therapies in the fourth quarter worth $96,000. 92.33% of the stock is owned by institutional investors and hedge funds.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.